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Abstract
Background: Diabetes and periodontal disease share common features in terms of inflammatory responses. Cur-
rent scientific evidence suggests that treatment of periodontal disease might contribute to glycemic control. The 
objective of the study is a review of the last three years.
Material and Methods: A literature search was performed in the MEDLINE (PubMed), Cochrane, and Scopus da-
tabases, for articles published between 01-01-2013 and 30-06-2015, applying the key terms “periodontal disease” 
AND “diabetes mellitus”. The review analyzed clinical trials of humans published in English and Spanish. 
Results: Thirteen clinical trials were reviewed, representing a total of 1,912 patients. Three of them had samples of 
<40 patients, making a total of 108 patients and the remaining ten samples had >40 patients, representing a total 
of 1,804. Only one article achieved a Jadad score of five. Seven articles (998 patients, 52.3% total), presented a sta-
tistically significant decrease in HbA1c (p<0.05) as a result of periodontal treatment. In the six remaining articles 
(representing 914 patients, 47.8% of the total), the decrease in HbA1c was not significant. Patient follow-up varied 
between 3 to 12 months. In three articles, the follow-up was of 3, 4, and 9 months, in two 6 and 12 months. 
Conclusions: The majority of clinical trials showed that radicular curettage and smoothing, whether associated 
with antibiotics or not, can improve periodontal conditions in patients with diabetes mellitus. However, few stud-
ies suggest that this periodontal treatment improves metabolic control. However, there is no clear evidence of a 
relation between periodontal treatment and improved glycemic control in patients with type 2 diabetes mellitus.  
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Introduction
Diabetes mellitus (DM) is a syndrome characterized by 
poor functioning of the carbohydrate, lipid and protein 
metabolism (1); its main characteristic is hyperglycemia 
(2). Hyperglycemia acts as the main cause of the pro-
gressive microvascular complications associated with 
diabetes (retinopathy, nephropathy, neuropathy) (3). 
There are various types of DM based on the complex 
interaction between genetic and environmental factors. 
Depending on the cause, factors that contribute to hy-
perglycemia can be: i) differences in insulin secretion; 
ii) reduction in glucose use; iii) increase in glucose pro-
duction (4). DM is classified as two main types: Type 
1 (DM1) and Type 2 (DM2). DM1 is associated with 
the destruction of β-pancreatic cells and it commonly 
appears in younger patients. DM2 is produced by a pro-
gressive decrease in sensitivity to insulin in its target 
tissues, and/or an insufficiency of the pancreas to in-
crease insulin production, developing into a resistance 
to insulin. This type makes up 90-95% of all cases of 
diabetes (4). DM2 has been catalogued as a twenty-first 
century epidemic for both its frequency and impact in 
terms of cardiovascular disease and peripheral neuropa-
thy. In recent years, it has been the main cause of death 
in the developed world (5,6); the prevalence of DM2 is 
very high in some western European countries (Ger-
many, Spain, Italy, France, and the United Kingdom). 
In Spain, a recent institutional study has found a preva-
lence of 12.5% (6).
Age is an important risk factor for type DM2. In Europe, 
37% of the population is aged over 50 years, and it is ex-
pected that this will increase to 44% by 2030 (6). For this 
reason, a dramatic increase in the numbers of diabetic 
patients is likely and foreseeable in the coming years (6).
DM diagnosis may be established through one of the fol-
lowing:  i) Fasting blood glucose (≥ 8 hours without food) 
(FBG) ≥ 126 mg/dl (7.0 mmol/L); if the patient presents 
figures of between 100 and 125 mg/dl, then this points 
to pre-diabetes. ii) Blood glucose ≥ 200 mg/dl (11.1 
mmol/L) two hours after oral glucose tolerance testing 
(OGTT). The test must be performed according to WHO 
guidelines established 1985, with 75 g anhydrous glucose 
dissolved in water after at least 8 hours without food. If 
the figures are between 149 and 199 mg/dl, this points to 
oral glucose intolerance. iii) If casual blood glucose is ≥ 
200 mg/dl (11.1 mmol/L) (registered at any moment dur-
ing the day, regardless of the time since food taken) and 
clinical DM symptoms are noted (poliuria, polidipsia, 
polifagia, unexplained weight loss) (4). 
The glycosylated hemoglobin test (HbA1c) is consid-
ered the gold standard method for monitoring glycemia, 
which facilitates metabolic management of DM patients 
(7). The test measures mean glycemia during the last 
2-3 months, allowing assessment of treatment efficacy 
and management by the patient him/herself (8).
Periodontal diseases comprise a group of pathologies 
characterized by periodontal inflammation caused by 
infection. In this way, they are induced by an accumula-
tion of micro-organism, mainly bacteria, which provoke 
activation of the immune system to combat the infec-
tion. They start with gingival inflammation; if its etio-
logical factors are not eliminated, the immune response 
will be more complex and the metabolism of the peri-
odontal tissues will be upset, resulting in loss of peri-
odontal support (9).
The inflammation involves an excessive production 
of inflammatory mediators, which end up causing tis-
sue destruction. Among these, the most important are: 
interleukin 1β (IL-1β) and 6 (IL-6); prostaglandin E2 
(PGE2); tumor necrosis factor alpha (TNFα), attaching 
to the receptor activator of nuclear factor kB (RANKL); 
matrix metalloproteinases (MMP); T cell regulatory 
cytokines (IL-12, IL-18); and chemokines (4,9). Inflam-
mation is not a characteristic limited to periodontitis, 
but of many other diseases, including diabetes. In this 
way, diabetes is associated with high levels of systemic 
inflammatory markers (9). 
The changes that diabetes can provoke in subgingival 
microbiota involve a greater prevalence of Porphy-
romonas gingivalis and Prevotella intermedia (10), the 
main bacteria involved in periodontal disease. Moreo-
ver, some research has cited DM as a risk factor for 
periodontal diseases (11,12), and among these, for apical 
periodontitis (13-15). 
Current scientific evidence suggests that the treatment 
of periodontal disease might be capable of contribut-
ing to glycemic control. But the magnitude and clinical 
significance of this possible effect calls for better qual-
ity investigation. Several researchers have shown that 
radicular curettage and smoothing (RCS) can improve 
the periodontal state of patients with diabetes. But in 
relation to the metabolic control of diabetes, the results 
do not appear to be conclusive. While some studies have 
found that periodontal improvement is associated with 
better metabolic control (16-21), others have not identi-
fied any beneficial effect (22,23). 
This systematic review examines clinical studies of 
humans that have investigated the possible correlation 
between periodontal treatment and glycemic control in 
patients with type 2 diabetes mellitus. The aim was to 
provide an answer to the clinical question: “Does peri-
odontal treatment influence the metabolic management 
of DM2?” 
Material and Methods  
A search was performed in the MEDLINE (PubMed) 
database for articles published between 01-01-2013 and 
30=06-2015 using the key search terms “Periodontal 
disease” AND “Diabetes mellitus”. The review includ-
ed articles published in English and Spanish describing 
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clinical studies of humans. Inclusion criteria were: i) a 
minimum sample size of  20 patients; ii) analytic data 
for HbA1c before and after periodontal intervention; iii) 
adequate description of non-surgical periodontal treat-
ment (based on radicular curettage and smoothing); iv) a 
follow-up of at least two months. After the initial search 
and application of inclusion criteria, a further search 
was performed in the Cochrane and Scopus databases, 
discarding any repeats. 
To evaluate the methodological quality of the clinical 
studies, levels of evidence and degrees of recommen-
dation were examined following established guides to 
good clinical practice (24). The articles’ internal validity 
was measured using the Jadad scale (25). A score of 0-5 
was assigned to each feature of the study, with a higher 
score indicating a higher quality of the contribution. 3-5 
were considered good quality, 2 acceptable, and 0-1 of 
poor quality. The selection and review process was car-
ried out by four reviewers (MS, EJ, JLL, FP)”
To collate data extracted from the studies, a specially 
drafted index card was prepared showing: author and 
year the study was carried out, evidence level accord-
ing to Jadad scale (25), sample size, inclusion criteria, 
exclusion criteria, distribution of groups, characteristics 
of periodontal treatment performed, follow-up period, 
periodontal and systemic parameters registered, effects 
of periodontal treatment on periodontal state, effects of 
periodontal treatment on metabolic values. From these 
index cards, the most relevant data were collated in a 
comparison table. 
Results
The initial search in the Medline database identified 377 
articles of which 30 clinical trials in humans were se-
lected. After applying the inclusion criteria this number 
reduced to nine (26-34). Searches in other databases 
(Cochrane and Scopus) obtained a total of 127 articles; 
when repetitions had been excluded and inclusion crite-
ria applied, a further four articles (35-38) were added, 
making a total of 13 (Fig. 1) (Table 1 and 1 continue). 
The 13 articles reviewed included a total of 1,912 pa-
tients. In three of the works, the sample was of less than 
 
Fig. 1. Flow diagram of selection process. 
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Table 1. Key characteristics of the studies reviewed.  
 
AUTHOR/ 
YEAR 
JADAD [ ] 
-Type of diabetes 
-Age 
-Criteria 
Follow-up Samples and groups   
Significant 
decrease in HbA1c 
(p<0.05) 
Telgi RL  et al., 
2013 (35) 
[4] 
-DM2 
-Age: 35-45 years 
-# teeth: 28; 
Slight and moderate 
periodontitis (periodontal 
sac 4-5 mm) 
 
3  months 
 
N=60  
-Group A: n=20; RCS + Mouthwash with 0.12% 
chlorhexidine (CHX) once a day and brushing twice a 
day 
-Group B: n= 20;  Mouthwash with 0.12% CHX once 
a day and brushing twice a day 
-Group C: n=20;  Brushing twice a day 
 
YES 
Santos VR et al.,  
2013 (27) 
[3] 
-DM2 
-Age:35-75  years 
-#  teeth: 15; 
Generalized chronic 
periodontitis  
12 months 
 
N=38 
-TG: n=19;  +  CHX solution 
-CG: n=19;  Curettage + placebo 
 
 
NO 
Engebretson SP  
et al., 2013 (26) 
[4] 
-DM2 
-Age: 35  years 
-# teeth: 16; 
Moderate-chronic 
periodontitis (probing depth 
>5mm) 
 
6 months 
 
N=514 
-TG: n= 257; curettage + ultrasonic scaling with 
anesthetic + CHX at start of study/periodontal 
therapy, at 3 months, and 6 months. 
-CG: n=257;  no treatment for 6 months  
 
 
 
NO 
Botero JE  et al., 
2013 (30) 
[4] 
 
 
 
 
-DM1 y DM2 
-Age: 57  years 
-# teeth: 10; 
Moderate periodontitis  
 
9 months 
 
N= 105 
-Group A: n=33; (Az-Sca) 500mg  azithromycin per 
day for 3 days + subgingival scaling   
-Group B: n= 37: (PB-Sca) 500mg placebo  per day 
for 3 days + subgingival scaling   
-Group C: n=35; (Az-Pro)  500mg  azithromycin per 
day for 3 days + supragingival prophylaxis   
YES 
Gaikwad SP  
et al., 2013 (37) 
[4] 
 
-DM2 
-Age: 30-70  years 
-# teeth: n/d; 
Generalized chronic 
periodontitis 
 
 
4 months 
 
N=50 
-TG: n= 25; RCS + 100 mg  doxycycline 
 Per day for 15 days 
-CG: n= 25; RCS  alone 
 
YES 
Engebretson S 
 et al., 2013 (28) 
[3] 
-DM2 
-Age: n/d 
-# teeth: n/d; 
Moderate-advanced 
periodontitis (> 5mm 
probing depth). Analytic 
values 
 
 
6 months 
 
N= 600 
-TG: n=300;  Immediate periodontal treatment or 
after 6 months  
-CG: n=300;   treatment after 6 months 
 
YES 
Pradeep AR 
 et al., 2013 (31) 
[4] 
-DM2 
-Age 30-50  years 
- # teeth 20; 
Advanced periodontitis  
 
 
9 months 
 
N=38 
-TG: n=19; RCS + 1.2%  simvastatin 
 
-CG: n= 19;  RCS  + placebo 
 
YES 
Raman RP et al., 
2014 (32) 
[2] 
-DM2 
-Age: 30 a 70  years 
-# teeth 12; 
Moderate-severe 
periodontitis. 
Periodontal sac ! 5mm. 
Insertion loss !4mm   
 
3 months 
 
N: 32 
-Group A:  n=15; RCS + 0.12% CHX for 14 days 
-Group B:  n=17; oral hygiene instruction  
 
 
 
 
YES 
Koromantzos PA  
 et al., 2014 (38) 
[1] 
-DM2 
-Age: 54 years 
-# teeth: n/d; 
Severe chronic periodontitis  
 
 
4 months 
 
N=126 
-TG: n= 66; RCS (with ultrasound and local 
anesthetic, two quadrants per session) 
-CG: n=60; oral hygiene instruction 
NO 
Gay IC et al., 2014 
(36) 
[3] 
-DM2 
-Age 51 -54 years 
-# teeth 23; 
Severe chronic periodontitis  
 
4 months 
N=126 
-TG: n=66; RCS 
-CG: n= 60; oral hygiene instruction 
 
NO 
Saengtipbovor NS 
et al.,  2014 (29) 
[2] 
-DM2 
-Age: > de 60 years 
-# teeth:16 
 
 
3 months 
N=113 
-TG: n=54; 20 minute lifestyle counseling and oral 
hygiene instruction by 15 minute video   
-CG: n= 59; Control group received a routine 
program  
YES 
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40 patients (representing 108 patients) (27,31,32) and 
in the other ten patient samples included more than 40 
patients (representing 1,804 patients) (26,28-30,33-38) 
(Table 1 and 1 continue).
Methodological quality evaluation found that only one 
article achieved a Jadad score of 5 (33); six articles ob-
tained Jadad scores of 4 (26,30,31,34,35,37), three a 
score of 3 (27,28,36), two a score of 2 (29,32) and a sin-
gle article scored 1 (38) (Table 1 and 1 continue). 
Seven of the works reviewed (representing 998 pa-
tients; 52.3% of the 1,912 patients studied), observed 
a statistically significant decrease in HbA1c (p<0.05) 
(28-32,35,37). In the remaining six articles (represent-
ing 914 patients, 47.8% of the total sample), the de-
crease in HbA1c did not prove statistically significant 
(26,27,33,34,36). Patient follow-up periods across the 
studies varied between three and twelve months, during 
which, periodontal parameters, metabolic management 
and the treatment established in each group were evalu-
ated. Follow-up periods were of three months (29,32,35), 
four months (36-38), six months (26,28), nine months 
(30,31,34) or twelve months (27,33). 
 
Discussion
The quality of the 13 articles was assessed using the 
Jadad scale (25) in order to reduce the risk of bias (Table 
1 and 1 continue). None of the studies reviewed (26-38) 
had considered their level of quality, although a system-
atic review by Mauri et al. (39) did apply the same cri-
terion to the articles analyzed. The Jadad scale awards a 
maximum score of 5. The present review obtained very 
similar results to Mauri et al. (39) regarding randomized 
trials: only one study by Miranda et al. (33) achieved a 
score of 5; six works scored 4 (26,30,31,34,35,37); six 
under 3. Mauri et al. (39) review another eight non-ran-
domized studies, obtained one work with a Jadad score 
of 2, three scoring 1, and four scoring 0.  
Various studies identified significant decreases in 
HbA1c values (28-32,35,37), although periodontal treat-
ment, sample size, follow-up period, and quality assess-
ment method were different in each study. 
Telgi et al. (35), with a Jadad score of 4, a sample size of 
60 patients diagnosed with moderate periodontitis, three 
groups, and a relatively short follow-up period of three 
months, found a significant decrease in HbA1c values in 
the two treatment groups (p<0.001). Both groups used a 
0.12% chlorhexidine mouthwash once a day, with tooth 
brushing twice daily (CG), while one group was also 
treated with radicular curettage and smoothing (RCS). 
A control group used tooth brushing alone, which failed 
to produce a statistically significant effect (p<0,009). 
In 2013, Engebrestson et al. (28) studied a large sample 
of 600 patients [Jadad score of 3], with a six-month fol-
low-up, also finding a significant decrease in metabolic 
values in the RCS group compared with the CG group 
in which treatment was postponed until the end of the 
six-month follow-up. 
Raman et al. (32) performed a clinical study of 32 pa-
tients divided into two groups: TG (RCS with 0.12% 
chlorhexidine mouthwash for 14 days) and CG (oral hy-
giene instruction), with a three-month follow-up. These 
authors also obtained a significant improvement in met-
abolic control. 
Saengtipbovn et al. (29) in a study [Jadad score of 2] of 
113 patients aged over 60 years, also with three-month 
follow-up, also obtained an improvement in metabolic 
control although the study did not provide a specific 
periodontal treatment but instead patients received life-
style counseling and specially targeted oral hygiene in-
struction by means of a video aimed at proving hygiene 
techniques.   
In studies that administered antimicrobials, such as Gaik-
wad et al. (37), [Jadad score of 4], who treated 50 patients 
with a four-month follow-up, also identified a significant 
DM2: Type 2 Diabetes Mellitus; TG: Treatment Group; CG: Control Group; N=:sample size; RCS: Radicular curettage and smoothing; 
CHX: Chlorhexidine; Az-Sca: Azithromycin plus subgingival scaling; PB-Sca: Placebo plus subgingival scaling; Az-Pro: Azithromycin 
plus prophylaxis; n/d: no data.
Table 1 Continue. Key characteristics of the studies reviewed.  
!
Miranda TS et al., 
2014 (33) 
[5] 
-DM2 
-Age 38-65 years 
-# teeth 15; 
Generalized periodontitis. 
Probing depth ! 5mm 
12 months 
N=58 
-TG: n=29; RCS + 400mg metronidazole 
 3 times a day + 500mg amoxicillin 
 3 times a day for 14 days 
-CG: n=29; RCS + placebo for 14 days 
 
NO 
López NJ et al., 
2014 (34) 
[4] 
-DM2 
-Age 47-70 years 
- # teeth 15; 
Chronic periodontitis.  
Probing depth  
! 4mm 
9 months 
N=52 
-TG: n=26; patients with DM2 and chronic 
periodontitis  
-CG: n=26; patients with cerebral paralysis  
Both groups received oral hygiene instruction, 
brushing 3 times a day and dental silk. Supragingival 
ultrasound and prophylaxis with rotating rubber cup 
and polishing paste.  
NO 
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improvement both in a group that underwent curettage 
and was administered doxycycline (TG), and in the con-
trol group (CG) that only underwent curettage.  
Botero et al. (30), [Jadad 4] produced findings that were 
similar in some aspects. This study had a sample of 105 
patients, who were treated with 500 mg azithromycin 
and monitored during a nine-month follow-up. This 
interesting study divided the sample into three groups: 
Group A (AZ-Sca, 500mg azithromycin per day for 
three days + subgingival scaling); Group B (PB-Sca, 
500mg placebo per day for three days + subgingival 
scaling); and Group C (AZ-Pro, 500mg azithromycin 
per day for three days + supragingival prophylaxis). So 
Groups A and C received azithromycin, with Group A 
receiving subgingival scaling (AZ-Sca) and Group C 
supragingival prophylaxis (AZ-Pro). The authors found 
significant improvement in the patients who received 
the antibiotic and underwent scaling (AZ-Sca). Group 
B (PB-Sca, placebo + subgingival scaling) did not un-
dergo any improvement in metabolic control. 
The last in this set of studies, Pradeep et al. (31), [Ja-
dad score of 4], studied 38 patients with a nine-month 
follow-up, dividing the sample into a treatment group 
(radicular curettage and smoothing plus 1.2% simvasta-
tin [as some authors have commented that it favors bone 
formation]) and a control group (CG) treated with RCS 
and a placebo. These authors also found a significant 
improvement in metabolic control.  
As for studies that failed to find a positive relation between 
periodontal treatment and metabolic control, Engebret-
son et al. (26), performed a study of 514 patients (Jadad 
score of 4) divided into two groups. One group postponed 
periodontal treatment by six months (CG), finding no im-
provement in metabolic control compared with the treat-
ment group (TG) who received RCS (both manual and 
ultrasonic) plus chlorhexidine at the time of periodontal 
treatment, at three months, and at six months. 
Another 2013 study by Santos et al. (27), [Jadad score of 
3], had a small sample of 38 patients but a long follow-
up of 12 months; these authors  did not find a significant 
reduction in HbA1c, in either of the two groups, one 
treated with curettage and the other with curettage plus 
chlorhexidine.  
The same results were obtained by Gay et al. (36) and 
Koromatzos et al. (38) [with Jadad scores of 3 and 1 re-
spectively] in their studies. Both included samples of 126 
patients each, and a follow-up of four months, establish-
ing treatment groups (TG) who underwent RCS and con-
trol groups (CG) who received oral hygiene instruction. 
Another study by Miranda et al. (33) [Jadad score of 5], 
with a sample of 58 patients and a long follow-up of 12 
months, failed to find a significant decrease in HbA1c in 
either of its two groups, TG (RSC + 500mg amoxicillin 
three times a day for 14 days) and  CG (RCS + placebo 
for 14 days).  
Lastly, López et al. (34), [Jadad score of 4] studied a 
sample of 52 patients with a nine-month follow-up, di-
vided into TG (DM2 patients with chronic periodontitis) 
and CG (patients with cerebral paralysis). Both groups 
received the same treatment by means of dental prophy-
laxis (oral hygiene instruction and dental cleaning three 
times a day using dental floss, supragingival ultrasonic 
descaling, and prophylaxis by rotating rubber cup and 
polishing paste) but no improvement in metabolic con-
trol was found.  
Coinciding with those authors who claim the absence 
of a significant relation between periodontal treatment 
and metabolic control, a 2014 meta-analysis by Wang 
et al. (40) analyzed four clinical trials with 71 patients 
treated with oral doxycycline plus RCS and 72 patients 
treated with RCS and a placebo, or RCS alone. The au-
thors conclude that metabolic control did not improve in 
any of the groups. 
Finally, the main limitation of the research consists in 
the fact that high sored studies defend a relationship or 
no-relationship, as well a wide range of inclusion crite-
ria, a different follow up time and a broad sample vari-
ability, making very difficult the results analysis.
Conclusions
Most clinical studies show that radicular curettage and 
smoothing, whether in combination with antibiotics or 
not, improve the periodontal state of patients with type 
2 diabetes mellitus. However, the improvement in the 
metabolic control through periodontal treatment is sup-
ported by seven of the reviewed articles and not vali-
dated by the rest of the articles (six).
Multicenter studies with larger patient samples and 
longer follow-up periods are needed to obtain results of 
greater meaning.  
On the basis of the present literature review, the ques-
tion “Does periodontal treatment influence the meta-
bolic management of DM2?” It is still without a clear 
answer and there can be no definitive conclusion regard-
ing the relation between periodontal treatment and im-
proved glycemic control of DM2 patients. 
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